New drug approach targets toxic protein clumps in Alzheimer's disease

Researchers have developed small molecule compounds that prevent amyloid-beta proteins from aggregating—a hallmark of Alzheimer's disease. The finding could accelerate development of disease-modifying treatments for a condition affecting millions globally, potentially opening a significant market opportunity for pharmaceutical companies pursuing neurodegeneration therapeutics.

Originaltitel: Small Molecule Decoys of Aggregation for Elimination of A?-Peptide Toxicity